Citation
Hongyang Sang, Jinlong Liu, Xifang Chen, Yingou Zeng. METTL16-dependent miR-146b-5p m6A modification remodeling sensitize NSCLC to osimertinib via activating PI3K/AKT signaling. // BMC Cancer. – 2025. – DOI: 10.1186/s12885-025-14041-y. – URL: https://doi.org/10.1186/s12885-025-14041-y
Hongyang Sang, Jinlong Liu, Xifang Chen, & Yingou Zeng (2025). METTL16-dependent miR-146b-5p m6A modification remodeling sensitize NSCLC to osimertinib via activating PI3K/AKT signaling. BMC Cancer. https://doi.org/10.1186/s12885-025-14041-y
Hongyang Sang, et al. “METTL16-dependent miR-146b-5p m6A modification remodeling sensitize NSCLC to osimertinib via activating PI3K/AKT signaling.” BMC Cancer, 2025. doi:10.1186/s12885-025-14041-y.
@article{Sang2025,
title = {METTL16-dependent miR-146b-5p m6A modification remodeling sensitize NSCLC to osimertinib via activating PI3K/AKT signaling},
author = {Sang, Hongyang and Liu, Jinlong and Chen, Xifang and Zeng, Yingou},
journal = {BMC Cancer},
year = {2025},
doi = {10.1186/s12885-025-14041-y},
url = {https://doi.org/10.1186/s12885-025-14041-y}
}